KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab plus chemotherapy vs placebo plus chemotherapy for metastatic TNBC

被引：54
|
作者：
Cortes, J. [1 ,2 ,3 ,4 ]
Cescon, D. W. [5 ]
Rugo, H. S. [6 ]
Im, S-A. [7 ]
Yusof, M. Md [8 ]
Gallardo, C. [9 ]
Lipatov, O. [10 ]
Barrios, C. H. [11 ]
Perez-Garcia, J. [1 ]
Iwata, H. [12 ]
Masuda, N. [13 ]
Otero, M. Torregroza [14 ]
Gokmen, E. [15 ]
Loi, S. [16 ,17 ]
Guo, Z. [18 ]
Zhou, X. [18 ]
Karantza, V. [18 ]
Pan, W. [18 ]
Schmid, P. [19 ]
机构：
[1] Int Breast Canc Ctr IBCC, Quiron Grp, Madrid, Spain
[2] Int Breast Canc Ctr IBCC, Quiron Grp, Barcelona, Spain
[3] Vall dHebron Inst Oncol, Barcelona, Spain
[4] Univ Europea Madrid, Fac Biomed & Hlth Sci, Dept Med, Madrid, Spain
[5] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
[6] Univ Calif San Francisco, Ctr Comprehens Canc, Dept Hematol Oncol, San Francisco, CA 94143 USA
[7] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[8] Pantai Hosp, Ctr Canc, Kuala Lumpur, Malaysia
[9] Arturo Lopez Perez Fdn, Inst Oncol, Santiago, Chile
[10] Republican Clin Oncol Dispensary, Dept Oncol, Republic Bashkortostan, Russia
[11] Pontificia Univ Catolica Rio Grande do Sul, Oncol Res Unit, Hosp Sao Lucas, Porto Alegre, RS, Brazil
[12] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi, Japan
[13] Natl Hosp Org Osaka Natl Hosp, Breast Oncol, Dept Surg, Osaka, Japan
[14] Oncomedica SA, Hematol & Oncol, Monteria, Colombia
[15] Ege Univ, Fac Med, Sch Med, Izmir, Turkey
[16] Peter MacCallum Canc Ctr, Div Canc Res, Melbourne, Vic, Australia
[17] Univ Melbourne, Sir Peter MacCallum Dept Med Oncol, Parkville, Vic, Australia
[18] Merck & Co Inc, Merck Res Labs, Kenilworth, NJ USA
[19] Ctr Expt Canc Med, Barts Canc Inst, London, England
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.2089
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA16
引用
收藏
页码：S1289 / S1290
页数：2
相关论文
共 50 条
  • [31] Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.
    Cortes, Javier
    Cescon, David W.
    Rugo, Hope S.
    Nowecki, Zbigniew
    Im, Seock-Ah
    Yusof, Mastura Md
    Gallardo, Carlos
    Lipatov, Oleg
    Barrios, Carlos Henrique
    Holgado, Esther
    Iwata, Hiroji
    Masuda, Norikazu
    Otero, Marco Torregroza
    Gokmen, Erhan
    Loi, Sherene
    Guo, Zifang
    Zhao, Jing
    Aktan, Gursel
    Karantza, Vassiliki
    Schmidi, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study
    McArthur, Heather
    Cortes, Javier
    Dent, Rebecca
    O'Shaughnessy, Joyce
    Pusztai, Lajos
    Kuemmel, Sherko
    Foukakis, Theodoros
    Park, Yeon Hee
    Hui, Rina
    Harbeck, Nadia
    Takahashi, Masato
    Untch, Michael
    Fasching, Peter A.
    Cardoso, Fatima
    Denkert, Carsten
    Zhu, Yalin
    Ding, Yu
    Pan, Wilbur
    Schmid, Peter
    CANCER RESEARCH, 2023, 83 (05)
  • [33] Benmelstobart with Anlotinib plus Chemotherapy as First-line Therapy for ES-SCLC: A Randomized, Double-blind, Phase III Trial
    Cheng, Y.
    Yang, R.
    Chen, J.
    Zhang, W.
    Xie, C.
    Hu, Q.
    Zhou, N.
    Huang, C.
    Wei, S.
    Sun, H.
    Li, X.
    Yu, Y.
    Lai, J.
    Yang, H.
    Fang, H.
    Chen, H.
    Zhang, P.
    Gu, K.
    Wang, Q.
    Shi, J.
    Yi, T.
    Xu, X.
    Ye, X.
    Wang, D.
    Xie, C.
    Liu, C.
    Zheng, Y.
    Lin, D.
    Zhuang, W.
    Lu, P.
    Yu, G.
    Li, J.
    Gu, Y.
    Li, B.
    Wu, R.
    Jiang, O.
    Wang, Z.
    Wu, G.
    Lin, H.
    Zhong, D.
    Xu, Y.
    Shu, Y.
    Wu, D.
    Chen, X.
    Wang, J.
    Wang, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S44 - S44
  • [34] Phase III KEYNOTE-590 study of chemotherapy plus pembrolizumab versus chemotherapy plus placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer
    Kato, K.
    Shah, M. A.
    Enzinger, P. C.
    Bennouna, J.
    Shen, L.
    Adenis, A.
    Sun, J-M.
    Cho, B. C.
    Ozguroglu, M.
    Kojima, T.
    Kostorov, V.
    Hierro, C.
    Zhu, Y.
    Shah, S.
    Bhagia, P.
    Doi, T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [35] KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC
    Wakelee, Heather A.
    Liberman, Moishe
    Kato, Terufumi
    Tsuboi, Masahiro
    Lee, Se-Hoon
    He, Jie
    Gao, Shugeng
    Chen, Ke-Neng
    Dooms, Christophe Alfons
    Majem, Margarita
    Eigendorff, Ekkehard
    Martinengo, Gaston Lucas
    Bylicki, Olivier
    Rodriguez-Abreu, Delvys
    Chaft, Jamie E.
    Novello, Silvia
    Yang, Jing
    Keller, Steven M.
    Samkari, Ayman
    Spicer, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA100 - LBA100
  • [36] Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for highrisk early-stage TNBC: Overall survival results from the phase III KEYNOTE-522 study
    Schmid, P.
    Cortes, J.
    Dent, R. A.
    McArthur, H. L.
    Pusztai, L.
    Kummel, S.
    Denkert, C.
    Park, Y. H.
    Hui, R.
    Harbeck, N.
    Takahashi, M.
    Im, S-A.
    Untch, M.
    Fasching, P. A.
    Cardoso, F.
    Zhao, J.
    Zhou, X.
    Tryfonidis, K. E.
    Aktan, G.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2024, 35 : 1204 - 1205
  • [37] Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
    Chen, Pingyu
    Wang, Xintian
    Zhu, Shengwen
    Li, Hongchao
    Rui, Mingjun
    Wang, Yingcheng
    Sun, Haikui
    Ma, Aixia
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [38] Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/ GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study
    Janjigian, Y. Y.
    Kawazoe, A.
    Bai, Y.
    Xu, J.
    Lonardi, S.
    Metges, J-P.
    Weber, P. E. Yanez
    Wyrwicz, L. S.
    Shen, L.
    Ostapenko, Y. V.
    Bilici, M.
    Chung, H. C.
    Shitara, K.
    Qin, S.
    Van Cutsem, E.
    Tabernero, J.
    Li, K.
    Shih, C-S.
    Bhagia, P.
    Rha, S. Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S851 - S852
  • [39] MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON OF TREMELIMUMAB plus DURVALUMAB plus CHEMOTHERAPY VS PEMBROLIZUMAB plus CHEMOTHERAPY AND NIVOLUMAB plus IPILIMUMAB plus CHEMOTHERAPY FOR FIRST-LINE METASTATIC NSCLC
    Johal, Sukhvinder
    Miranda, Miguel
    Sarbajna, Tina
    Shi, Xiaojin
    Greystoke, Alastair
    Johnson, Melissa
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A608 - A608
  • [40] Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
    Shitara, Kohei
    Van Cutsem, Eric
    Bang, Yung-Jue
    Fuchs, Charles
    Wyrwicz, Lucjan
    Lee, Keun-Wook
    Kudaba, Iveta
    Garrido, Marcelo
    Chung, Hyun Cheol
    Lee, Jeeyun
    Castro, Hugo Raul
    Mansoor, Wasat
    Braghiroli, Maria Ignez
    Karaseva, Nina
    Caglevic, Christian
    Villanueva, Luis
    Goekkurt, Eray
    Satake, Hironaga
    Enzinger, Peter
    Alsina, Maria
    Benson, Al
    Chao, Joseph
    Ko, Andrew H.
    Wainberg, Zev A.
    Kher, Uma
    Shah, Sukrut
    Kang, S. Peter
    Tabernero, Josep
    JAMA ONCOLOGY, 2020, 6 (10) : 1571 - 1580
12345